Journal: Scientific Reports
Article Title: High-Risk neuroblastoma therapeutics Topotecan and 13-cis-Retinoic acid modulate autophagy and induce DNA damage response in hematopoietic stem cells and monocytes
doi: 10.1038/s41598-025-19454-0
Figure Lengend Snippet: 13cisRA and Topotecan promote expansion of CB-HSPCs into granulocytic cells in vitro. a Expansion of HSPCs in liquid media culture for 5 and 7 days treated with topotecan (blue), 13cisRA (red), or left untreated (NT, black). Data are represented as median ± IQR, n = 6. Statistical significance was tested by two-way ANOVA with Sidak’s multiple comparison test comparing treatments to NT at individual timepoints (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Abbreviations: HSC, hematopoietic stem cell; MPP, multipotent progenitor cell; MLP, multi-lymphoid progenitor cell; CMP, common myeloid progenitor cell; MEP, megakaryocyte-erythroid progenitor cell; GMP, granulocyte-monocyte progenitor cell. b Expression of CEBPA, GATA1, and SPI1 after 7 days of HSPCs treated with topotecan (blue), 13cisRA (red), or left untreated (NT, black) in liquid culture. Data are represented as median ± IQR, n = 6. Statistical significance was tested by paired parametric t-test (*p < 0.05, **p < 0.01, ***p < 0.001).
Article Snippet: The following TaqMan probes were used: CDKN1A (Hs00355782_m1), CDKN2A (p16 INK4A splicing isoform, Hs02902543_mH), CDKN2A (p14 ARF splicing isoform, Hs99999189_m1), TP53 (Hs01034249_m1), GATA1 (Hs01085823_m1), CEBPA (Hs00269972_s1), SPI1 (Hs02786711_m1), POT1 (Hs00209984_m1), TERF1 (Hs00819517_mH), TERF2 (Hs01030567_m1), TINF2 (Hs01554307_g1), RARA (Hs00940446_m1), RARB (Hs00977140_m1), RARG (Hs01559234_m1), ATG5 (Hs00169468_m1), ATG7 (Hs00893766_m1), SIRT1 (Hs01009006_m1), SIRT3 (Hs00953477_m1) and GAPDH (Hs02758991_g1).
Techniques: In Vitro, Comparison, Expressing